athenahealth price target lowered to $90 from $120 at Oppenheimer Oppenheimer reduced its price target on athenahealth after the stock dropped following David Einhorn's pessimistic presentation about it. Oppenheimer believes that the company's margins are "structurally disadvantaged" versus those of pure software as a service companies. The firm keeps an Underperform rating on the stock.
News For ATHN From The Last 14 Days
Check below for free stories on ATHN the last two weeks.